Market Overview

UPDATE: Piper Jaffray Initiates Quidel at Overweight on Long-Term Outlook

Related QDEL
New Stocks Make Most Attractive/Dangerous Lists For May
Investors are betting against Quidel (QDEL), Should You? - Tale of the Tape

Piper Jaffray initiated coverage on Quidel (NASDAQ: QDEL) with an Overweight rating and a $26 price target.

Piper Jaffray said, "Our rating is based on Quidel's long-term diversification plan, initially building on the momentum from its Sofia launch and more importantly penetrating the molecular diagnostics market with its pipeline Wildcat instrument. Our $26 price target is based on 4.3x F2013 EV/ revenue, in-line with its small-cap diagnostics peer group."

Quidel closed at $18.17 on Wednesday.

Latest Ratings for QDEL

DateFirmActionFromTo
Nov 2014Canaccord GenuityMaintainsBuy
Jul 2014JP MorganMaintainsNeutral
Jul 2014Raymond JamesMaintainsOutperform

View More Analyst Ratings for QDEL
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (QDEL)

Around the Web, We're Loving...

Get Benzinga's Newsletters